dagorret.net
Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia - Carlos Dagorret Notes
Pfizer Inc announced today that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002). However, the study did not meet its primary …